MIRM - Mirum stock tumbles 20% premarket on failed drug study
2023-12-18 09:29:13 ET
More on Mirum Pharmaceuticals
- Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
- Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
- JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower
- Mirum draws $60 target from Morgan Stanley on liver disease prospects
- Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals
For further details see:
Mirum stock tumbles 20% premarket on failed drug study